The impact of scheduling restrictions on non-prescribed alprazolam use among people who frequently inject drugs
These slides accompanied Raimondo Bruno's short poster presentation at the 2014 National Drug Trend
These slides accompanied Raimondo Bruno's short poster presentation at the 2014 National Drug Trend
This resource was presented at the 2013 National Drug Trends Conference.
Key Findings
NDARC Technical Report No. 50 (1997)
NDARC Technical Report No. 35 (1996)
EXECUTIVE SUMMARY
NDARC Technical Report No. 33 (1996)
NDARC Technical Report No. 27 (1995)
EXECUTIVE SUMMARY
The number of sudden or unnatural deaths involving the high potency anti-anxiety medication alprazolam (including Xanax) has increased dramatically since 2009, a study by the National Drug and Alcohol Research Centre at UNSW has shown.
There has been a great deal of clinical concern regarding alprazolam (Xanax) abuse, so much so that the Therapeutic Goods Administration reclassified the drug effective 1 February 2014 from Schedule 4 (prescription only medicine) to Schedule 8 (controlled drug).